Keyphrases
Multiple Myeloma
89%
Bortezomib
44%
Relapsed or Refractory multiple Myeloma
39%
Multiple Myeloma Patients
38%
Overall Survival
37%
Acute Myeloid Leukemia
32%
Amyloidosis
31%
Light Chain Amyloidosis
30%
AL Amyloidosis
27%
Relapsed or Refractory
25%
Progression-free Survival
24%
Lenalidomide
22%
Chimeric Antigen Receptor T Cells (CAR-T)
21%
Daratumumab
20%
Israeli
19%
Clinical Outcomes
17%
Chronic Lymphocytic Leukemia
17%
High Risk
17%
Myeloma
16%
B-cell Maturation Antigen
15%
Minimal Residual Disease
15%
Plasma Cells
15%
Confidence Interval
15%
Protease Inhibitors
15%
Primary Central Nervous System Lymphoma (PCNSL)
14%
Acute Lymphoblastic Leukemia
13%
Azacitidine
13%
Waldenström Macroglobulinemia
13%
Clinical High Risk
13%
Immunomodulatory Drugs (IMiDs)
12%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
90%
Overall Survival
37%
Amyloidosis
37%
Bortezomib
37%
Dexamethasone
29%
Progression Free Survival
28%
AL Amyloidosis
28%
Acute Myeloid Leukemia
27%
Disease
27%
Chimeric Antigen Receptor
24%
Clinical Trial
24%
Lenalidomide
21%
B Cell Maturation Antigen
20%
Remission
17%
Infection
16%
Adverse Event
14%
Retrospective Study
14%
Minimal Residual Disease
14%
Chemotherapy
13%
Hematologic Malignancy
13%
Myelodysplastic Syndrome
13%
Azacitidine
13%
Methotrexate
13%
Belantamab Mafodotin
13%
Daratumumab
11%
Primary Central Nervous System Lymphoma
10%
Rituximab
10%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
10%
Medicine and Dentistry
Multiple Myeloma
100%
Disease
48%
Amyloidosis
41%
Overall Survival
37%
Progression Free Survival
29%
Acute Myeloid Leukemia
27%
Bortezomib
24%
Myeloma
24%
Clinical Trial
21%
Light Chain
20%
Dexamethasone
20%
B Cell Maturation Antigen
19%
Immunoglobulin Producing Cell
15%
Minimal Residual Disease
15%
Cancer
14%
AL Amyloidosis
14%
Lenalidomide
14%
Acute Lymphoblastic Leukemia
13%
B-Cell Chronic Lymphocytic Leukemia
13%
Retrospective Study
13%
Waldenström's Macroglobulinemia
13%
Belantamab Mafodotin
13%
Chimeric Antigen Receptor T-Cell
12%
Diffuse Large B-Cell Lymphoma
11%
Leukemia
11%
Central Nervous System
10%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
10%
Chemotherapy
10%